Hormone replacement therapy and prevention of nonvertebral fractures: A meta-analysis of randomized trials

JAMA

Volumn 285, Issue 22, 2001, Pages 2891-2897

  Torgerson, D J ^a   Bell Syer, S E M ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; GESTAGEN; MESTRANOL;

AGE; CLINICAL TRIAL; DATA BASE; FOLLOW UP; FRACTURE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; META ANALYSIS; NONVERTEBRAL FRACTURE; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; WRIST FRACTURE;

EID: 0035854025     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.285.22.2891     Document Type: Review

References (45)

1. Effect of age on reasons for initiation and discontinuation of hormone replacement therapy
2. Estrogen replacement therapy and fractures in older women
3. Hormone replacement therapy and the risk of hip fracture: Population-based case-control
4. Hormone replacement therapy and the risk of first hip fracture
5. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women: Results of the Danish Osteoporosis Prevention Study
6. Treatment of postmenopausal osteoporosis with transdermal estrogen
7. Events per person year: A dubious concept
8. Randomized trial of estrogen and progestin for secondary prevention of coronary heart disease in postmenopausal women
9. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women: A 5-year randomised trial
10. The Women's Health Initiative: A heart-to-HRT conversation
11. Hormone replacement therapy
12. Osteoporosis: Cost-effectiveness analysis and review of the evidence for prevention, diagnosis and treatment
13. Do estrogens effectively prevent osteoporosis-related fractures?
14. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: Pooled data from clinical trials
15. Assessing the quality of reports of randomized trials: Implications for the conduct of meta-analysis
16. Systematic review: Why sources of heterogeneity in meta-analysis should be investigated
17. Estrogen replacement therapy I: A 10-year prospective study in the relationship to osteoporosis
18. A four-year randomized controlled trial of hormone replacement therapy and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis
19. Monoflurophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: A randomized study
20. Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy
21. A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss
22. Effects on bone mass after eight years of hormonal replacement therapy
23. Alendronate and estrogen-progestin in the long-term prevention of bone loss: Four-year results from the Early Postmenopausal Intervention Cohort Study
24. Effect of hormone therapy on bone mineral density
25. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
26. Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism
27. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial
28. Low-dose esterified estrogen therapy: Effects on bone, plasma estradiol concentrations, endometrium, and lipid levels
29. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women: A randomized, controlled trial
30. A combination of low doses of 17b-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women
31. Early response in biochemical makers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women
32. Estrogen treatment of patients with established postmenopausal osteoporosis
33. Effects of hormone replacement therapy and high impact physical exercise on bone/muscle ratio in postmenopausal women
34. Bone conserving effects of oestrogen are dose-dependent for age and time since menopause
35. The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-178 and dydrogesterone
36. Effect of estrogen, calcitriol and a combination of estrogen and calcitriol on bone mineral density and fractures in elderly women
37. Geographic differences in bone turnover: Data from a multinational study in healthy postmenopausal women
38. Digitized mammography: A clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo
39. Postmenopausal oestrogens protect against fractures of hip and distal radius: A case-control study
40. Variation in the efficacy of hormone replacement therapy in the prevention of hip fracture
41. Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS)
42. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
43. Effect of risedronate on the risk of hip fracture in elderly women
44. Validity of self-reported fractures: Results from a prospective study in men and women across Europe